SG11202109157TA - Pyrazolopyridine derivatives as inhibitors of pask - Google Patents
Pyrazolopyridine derivatives as inhibitors of paskInfo
- Publication number
- SG11202109157TA SG11202109157TA SG11202109157TA SG11202109157TA SG11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- pyrazolo
- pyridin
- pharmaceutically acceptable
- carboxylate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1902490.0A GB201902490D0 (en) | 2019-02-25 | 2019-02-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| PCT/EP2020/054122 WO2020173739A1 (en) | 2019-02-25 | 2020-02-17 | Pyrazolopyridine derivatives as inhibitors of pask |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109157TA true SG11202109157TA (en) | 2021-09-29 |
Family
ID=65998935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109157TA SG11202109157TA (en) | 2019-02-25 | 2020-02-17 | Pyrazolopyridine derivatives as inhibitors of pask |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220144823A1 (enExample) |
| EP (1) | EP3931191B1 (enExample) |
| JP (1) | JP2022525121A (enExample) |
| KR (1) | KR20210134001A (enExample) |
| CN (1) | CN113474344A (enExample) |
| AR (1) | AR124749A1 (enExample) |
| AU (1) | AU2020229041A1 (enExample) |
| BR (1) | BR112021016642A2 (enExample) |
| CA (1) | CA3130154A1 (enExample) |
| CO (1) | CO2021010485A2 (enExample) |
| ES (1) | ES2963409T3 (enExample) |
| GB (1) | GB201902490D0 (enExample) |
| IL (1) | IL285751A (enExample) |
| MA (1) | MA55074A (enExample) |
| MX (1) | MX2021010093A (enExample) |
| PH (1) | PH12021552032A1 (enExample) |
| SG (1) | SG11202109157TA (enExample) |
| TW (1) | TW202045505A (enExample) |
| WO (1) | WO2020173739A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022070288A1 (ja) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | 含窒素二環化合物 |
| WO2025143152A1 (ja) * | 2023-12-27 | 2025-07-03 | 全薬工業株式会社 | チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4310109B2 (ja) * | 2001-04-26 | 2009-08-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物 |
| EP2320907A4 (en) * | 2008-08-05 | 2012-09-05 | Merck Sharp & Dohme | THERAPEUTIC COMPOUNDS |
| US9139589B2 (en) * | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2014066795A1 (en) * | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| CN107257796A (zh) * | 2014-12-02 | 2017-10-17 | 拜耳医药股份有限公司 | 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途 |
| WO2018200855A1 (en) * | 2017-04-27 | 2018-11-01 | The Brigham And Women's Hospital, Inc. | Novel alk2 inhibitors and methods for inhibiting bmp signaling |
-
2019
- 2019-02-25 GB GBGB1902490.0A patent/GB201902490D0/en not_active Ceased
-
2020
- 2020-02-17 WO PCT/EP2020/054122 patent/WO2020173739A1/en not_active Ceased
- 2020-02-17 SG SG11202109157TA patent/SG11202109157TA/en unknown
- 2020-02-17 JP JP2021555034A patent/JP2022525121A/ja active Pending
- 2020-02-17 PH PH1/2021/552032A patent/PH12021552032A1/en unknown
- 2020-02-17 CN CN202080016700.3A patent/CN113474344A/zh active Pending
- 2020-02-17 EP EP20706194.6A patent/EP3931191B1/en active Active
- 2020-02-17 MX MX2021010093A patent/MX2021010093A/es unknown
- 2020-02-17 US US17/433,503 patent/US20220144823A1/en not_active Abandoned
- 2020-02-17 CA CA3130154A patent/CA3130154A1/en active Pending
- 2020-02-17 ES ES20706194T patent/ES2963409T3/es active Active
- 2020-02-17 KR KR1020217030814A patent/KR20210134001A/ko not_active Ceased
- 2020-02-17 AU AU2020229041A patent/AU2020229041A1/en not_active Abandoned
- 2020-02-17 MA MA055074A patent/MA55074A/fr unknown
- 2020-02-17 BR BR112021016642A patent/BR112021016642A2/pt not_active IP Right Cessation
- 2020-02-21 AR ARP200100485A patent/AR124749A1/es not_active Application Discontinuation
- 2020-02-24 TW TW109105861A patent/TW202045505A/zh unknown
-
2021
- 2021-08-10 CO CONC2021/0010485A patent/CO2021010485A2/es unknown
- 2021-08-22 IL IL285751A patent/IL285751A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3130154A1 (en) | 2020-09-03 |
| AU2020229041A1 (en) | 2021-10-21 |
| PH12021552032A1 (en) | 2022-11-14 |
| AR124749A1 (es) | 2023-05-03 |
| IL285751A (en) | 2021-10-31 |
| EP3931191B1 (en) | 2023-10-04 |
| CN113474344A (zh) | 2021-10-01 |
| CO2021010485A2 (es) | 2021-08-19 |
| US20220144823A1 (en) | 2022-05-12 |
| EP3931191A1 (en) | 2022-01-05 |
| KR20210134001A (ko) | 2021-11-08 |
| BR112021016642A2 (pt) | 2021-11-03 |
| GB201902490D0 (en) | 2019-04-10 |
| JP2022525121A (ja) | 2022-05-11 |
| MX2021010093A (es) | 2021-09-21 |
| WO2020173739A1 (en) | 2020-09-03 |
| ES2963409T3 (es) | 2024-03-27 |
| TW202045505A (zh) | 2020-12-16 |
| MA55074A (fr) | 2022-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2664985T3 (es) | Compuestos y métodos para modulación de quinasa, e indicaciones de los mismos | |
| AU2022270061B2 (en) | Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| AU2024227155A1 (en) | Carboxy-benzimidazole GLP-1R modulating compounds. | |
| KR102924294B1 (ko) | 아졸-융합된 피리다진-3(2h)-온 유도체 | |
| CA3219984A1 (en) | Glp-1 receptor agonist and composition and use thereof | |
| IL283979A (en) | 1,3-thiazol-2-yl substituted benzamides | |
| CA3094700A1 (en) | Compounds for treating huntington's disease | |
| EP3168219B1 (en) | Pyridone derivative having tetrahydropyranyl methyl group | |
| KR102828717B1 (ko) | PI3K-γ 저해제로서의 아미노피라진 다이올 화합물 | |
| AU2018278928A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| JP7549597B2 (ja) | Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体 | |
| AU2016322848B2 (en) | 1-phenylpyrrolidin-2-one derivatives as perk inhibitors | |
| KR20250172881A (ko) | 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도 | |
| PH12015502055B1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| RS61012B1 (sr) | Aromatični derivati sulfonamida | |
| AU2008331733A1 (en) | [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta | |
| WO2007037534A1 (ja) | ２－へテロアリール置換インドール誘導体 | |
| MX2010013743A (es) | Derivados de imidazopiridina como inhibidores de receptor de tirosina-cinasas. | |
| AU2015276264A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| WO2016010897A1 (en) | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors | |
| KR20250057021A (ko) | 암의 치료를 위한 fgfr3 억제제로서의 피라졸로[1,5-a]피리딘 및 이미다조[1,2-a]피리딘 유도체 | |
| AU2024225909A1 (en) | Covalent modifiers of akt1 and uses thereof | |
| CA3253414A1 (en) | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | |
| CA3162281A1 (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | |
| EP3931191B1 (en) | Pyrazolopyridine derivatives as inhibitors of pask |